Biomarker-Enhanced Early Single-Time-Point Dosimetry for Lu-177-PSMA Therapy Using Deep Learning (EANM 2026) - Sep 29, 2026 - Abstract #EPS-007; Pres time: Oct 18, 2026; 08:00 AM - 09:30 AM; Location: Hall G2; "Materials and Twenty-one patients with metastatic castration-resistant prostate cancer treated with 1-6 cycles of Lu-177-PSMA-617 therapy were retrospectively included, resulting a total of 86 cycles... The integration of biomarker information and OTWR significantly improves dosimetric accuracy, achieving the lowest errors for both kidneys and tumors and demonstrating strong potential for practical early STP implementation in Lu-177 PSMA therapy."
Biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor
|
|
Y. Liu 1; A. Afshar-Oromieh 2; A. Rominger 2; K. Shi 2; G. Mok 1
|